Is receiving an monoamine oxidase-inhibitors (MAOI) or any drug which has significant MAOI activity (e.g., meperidine, linezolid, methylene blue) within the  days before screening, or has a history of Serotonin Syndrome after receiving serotonergic drugs.
Subjects being treated with a monoamine oxidase inhibitor (MAOI), or drug which has significant MAOI activity (e.g., meperidine, linezolid, methylene blue) within  weeks prior to screening
Subjects receiving monoamine oxidase (MAO)-inhibitors (MAOI) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the  days before screening
Subjects receiving monoamine oxidase inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the  days before screening
Subjects receiving monoamine oxidase inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) from  days prior to day  through  weeks after the final dose of epacadostat has been administered
DOSE ESCALATION COHORT: Subjects receiving monoamine oxidase Inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the  days before screening
DOSE EXPANSION COHORT: Subjects receiving monoamine oxidase Inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the  days before screening
Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the  days before screening
